Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Wist

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trialU Jungnelius, U Ringborg, S Aamdal, et al.
British Journal of Cancer|June 27, 2002
Tumour microvessel density as predictor of chemotherapy response in breast cancer patientsO Tynninen, J Sjöström, K von Boguslawski, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II StudyG Saeter, T A Alvegård, O R Monge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerJ Sjöström, C Blomqvist, P Heikkilä, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancerJ Sjöström, J Collan, K von Boguslawski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Risk-adapted treatment of clinical stage 1 non-seminoma testis cancerO Klepp, O Dahl, P Flodgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyN Wilking, E Lidbrink, T Wiklund, et al.
Lancet (London, England)|October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 studyJ Bergh, T Wiklund, B Erikstein, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trialU Jungnelius, U Ringborg, S Aamdal, et al.
British Journal of Cancer|June 27, 2002
Tumour microvessel density as predictor of chemotherapy response in breast cancer patientsO Tynninen, J Sjöström, K von Boguslawski, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II StudyG Saeter, T A Alvegård, O R Monge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerJ Sjöström, C Blomqvist, P Heikkilä, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancerJ Sjöström, J Collan, K von Boguslawski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Risk-adapted treatment of clinical stage 1 non-seminoma testis cancerO Klepp, O Dahl, P Flodgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyN Wilking, E Lidbrink, T Wiklund, et al.
Lancet (London, England)|October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 studyJ Bergh, T Wiklund, B Erikstein, et al.
Pageof 9